<DOC>
	<DOCNO>NCT01895322</DOCNO>
	<brief_summary>To investigate efficacy , pharmacokinetics , pharmacodynamics , safety OPC-41061 patient chronic renal failure undergo peritoneal dialysis , use daily urine volume , body weight , edematous condition parameter conduct dose escalation every 2 day reach dose achieves urine volume increase perform 5-day repeat administration fix dose , final dose use dose escalation period .</brief_summary>
	<brief_title>Open-label Dose-finding Trial OPC-41061 Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Patients diagnose chronic renal failure Patients undergoing peritoneal dialysis ( continuous ambulatory peritoneal dialysis [ CAPD ] ) Patients , undergo peritoneal dialysis , receive follow medical treatment fluid overload [ OR : hypervolemia ] insufficient effect : Addition increase diuretic Increase concentration volume peritoneal dialysis fluid Increase number change peritoneal dialysis fluid Subjects , together partner , able practice one specify contraceptive method 4 week final trial drug administration Subjects inpatient admit trial site duration trial period Subjects follow disease , complication , symptom : Suspected hypovolemia Daily urine volume le 200 mL Urination impair due urinary tract stricture , urinary calculus , tumor urinary tract , cause Cardiac function NYHA class 4 Subjects follow medical history : History cerebrovascular disorder coronary artery disease within 4 week prior inform consent History hypersensitivity idiosyncratic reaction benzazepine derivative mozavaptan hydrochloride benazepril hydrochloride Subjects follow abnormal laboratory value : Hemoglobin low 9.0 g/dL , total bilirubin high 3.0 g/dL , ALT ( GPT ) AST ( GOT ) 2 time upper limit reference range trial site , serum sodium high upper limit reference range trial site , serum sodium lower 125 mEq/L , serum potassium high 5.5 mEq/L Subjects follow condition , concomitant disease , symptom : defect diaphragm hemorrhagic diathesis due uremia suspect lactic acid metabolic disorder suspect peritonitis , peritoneal damage , peritoneal adhesion , disorder intraabdominal organ Subjects undergone peritoneal dialysis 8 year longer Subjects schedule undergo hemodialysis concomitant use hemodialysis , renal transplantation Subjects participate clinical trial postmarketing clinical study within 30 day prior informed consent Subjects previously receive OPC41061 Subjects unable sense thirst difficulty fluid food intake Female subject pregnant , possibly pregnant , nursing , plan become pregnant trial period Subjects otherwise judge investigator subinvestigator inappropriate inclusion trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Tolvaptan</keyword>
	<keyword>dialysis</keyword>
</DOC>